Work

Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition

Year: 2021

Type: article

Source: Kidney International

DOI: 10.1016/j.kint.2021.08.022

Authors: Yuntao Bai, Ji Young Kim, Bijay Bisunke, Laura A. Jayne, Josie A. Silvaroli, Michael S. Balzer, Megha Gandhi, Kevin M. Huang, Veronika Sander, Jason Prosek, Rachel E. Cianciolo, Sharyn D. Baker, Alex Sparreboom, Kenar D. Jhaveri, Katalin Susztak, Amandeep Bajwa, Navjot Singh Pabla

Institutions: The Ohio State University, University of Tennessee Health Science Center, University of Pennsylvania, University of Auckland, The Ohio State University Wexner Medical Center, Northwell Health, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell

Language: English

Topic: Acute Kidney Injury Research

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: American Heart Association, Pelotonia, National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: Mitochondrial Therapy for Kidney Injury, (9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics, G3586134318, Cancer Center Support Grant

OpenAlex ID: W3199980127

FWCI: 3.34

Cites: 75

Cited by: 31

Related to: 10